TY - JOUR
T1 - Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.
AU - Baldwin, David S
AU - Anderson, Ian M
AU - Nutt, David J
AU - Allgulander, Christer
AU - Bandelow, Borwin
AU - den Boer, Johan A
AU - Christmas, David M
AU - Davies, Simon
AU - Fineberg, Naomi
AU - Lidbetter, Nicky
AU - Malizia, Andrea
AU - McCrone, Paul
AU - Nabarro, Daniel
AU - O'Neill, Catherine
AU - Scott, Jan
AU - van der Wee, Nic
AU - Wittchen, Hans-Ulrich
PY - 2014/5
Y1 - 2014/5
N2 - This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and clinical management, including recognition, acute treatment, longer-term treatment, combination treatment, and further approaches for patients who have not responded to first-line interventions. A consensus meeting involving international experts in anxiety disorders reviewed the main subject areas and considered the strength of supporting evidence and its clinical implications. The guidelines are based on available evidence, were constructed after extensive feedback from participants, and are presented as recommendations to aid clinical decision-making in primary, secondary and tertiary medical care. They may also serve as a source of information for patients, their carers, and medicines management and formulary committees.
AB - This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and clinical management, including recognition, acute treatment, longer-term treatment, combination treatment, and further approaches for patients who have not responded to first-line interventions. A consensus meeting involving international experts in anxiety disorders reviewed the main subject areas and considered the strength of supporting evidence and its clinical implications. The guidelines are based on available evidence, were constructed after extensive feedback from participants, and are presented as recommendations to aid clinical decision-making in primary, secondary and tertiary medical care. They may also serve as a source of information for patients, their carers, and medicines management and formulary committees.
KW - Anticonvulsants
KW - antidepressants
KW - antipsychotics
KW - anxiety disorders
KW - anxiolytics
KW - benzodiazepines
KW - cognitive behaviour therapy
KW - evidence-based guidelines
KW - generalised anxiety disorder
KW - obsessive-compulsive disorder
KW - panic disorder
KW - post-traumatic stress disorder
KW - pregabalin
KW - selective serotonin reuptake inhibitor
KW - separation anxiety disorder
KW - serotonin-noradrenaline reuptake inhibitor
KW - social anxiety disorder
KW - specific phobia
KW - treatment
U2 - 10.1177/0269881114525674
DO - 10.1177/0269881114525674
M3 - Article
C2 - 24713617
SN - 1461-7285
VL - 28
JO - Journal of psychopharmacology (Oxford, England)
JF - Journal of psychopharmacology (Oxford, England)
IS - 5
ER -